Incyte (NASDAQ:INCY) Price Target Cut to $94.00 by Analysts at UBS Group

Incyte (NASDAQ:INCY) had its target price cut by UBS Group from $104.00 to $94.00 in a research note released on Wednesday morning,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on INCY. Royal Bank Of Canada reduced their target price on Incyte from $95.00 to $92.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 11th. Barclays reaffirmed an “overweight” rating on shares of Incyte in a research note on Tuesday. Wells Fargo & Company reduced their price objective on shares of Incyte from $107.00 to $101.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 11th. Truist Financial set a $103.00 target price on shares of Incyte in a report on Wednesday, December 24th. Finally, Morgan Stanley set a $102.00 target price on shares of Incyte in a research report on Wednesday, February 11th. Nine research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $104.89.

Incyte Stock Performance

INCY opened at $92.23 on Wednesday. The company has a quick ratio of 3.25, a current ratio of 3.32 and a debt-to-equity ratio of 0.01. Incyte has a 12-month low of $53.56 and a 12-month high of $112.29. The business has a 50 day moving average of $99.56 and a 200-day moving average of $96.94. The stock has a market cap of $18.35 billion, a price-to-earnings ratio of 14.39, a PEG ratio of 0.72 and a beta of 0.84.

Incyte (NASDAQ:INCY) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). The business had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.35 billion. Incyte had a return on equity of 26.34% and a net margin of 25.03%.The firm’s revenue was up 27.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.43 earnings per share. On average, equities research analysts expect that Incyte will post 4.86 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Mohamed Khairie Issa sold 10,856 shares of the business’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $109.07, for a total transaction of $1,184,063.92. Following the sale, the executive vice president owned 66,132 shares in the company, valued at $7,213,017.24. The trade was a 14.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Pablo J. Cagnoni sold 18,667 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $94.24, for a total value of $1,759,178.08. Following the completion of the transaction, the insider directly owned 234,800 shares of the company’s stock, valued at approximately $22,127,552. The trade was a 7.36% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 17.80% of the company’s stock.

Institutional Trading of Incyte

Several hedge funds and other institutional investors have recently made changes to their positions in the company. AustralianSuper Pty Ltd acquired a new stake in Incyte in the third quarter valued at $18,085,000. Rakuten Investment Management Inc. acquired a new position in Incyte during the 3rd quarter worth about $14,646,000. LBP AM SA lifted its holdings in Incyte by 33.6% during the 3rd quarter. LBP AM SA now owns 238,705 shares of the biopharmaceutical company’s stock worth $20,245,000 after buying an additional 59,974 shares during the period. Massachusetts Financial Services Co. MA grew its position in shares of Incyte by 38.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 387,605 shares of the biopharmaceutical company’s stock valued at $32,873,000 after buying an additional 108,645 shares during the last quarter. Finally, Nordea Investment Management AB increased its stake in shares of Incyte by 941.8% in the fourth quarter. Nordea Investment Management AB now owns 322,223 shares of the biopharmaceutical company’s stock valued at $31,874,000 after buying an additional 291,293 shares during the period. 96.97% of the stock is currently owned by institutional investors.

Key Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and lifted its price target to $135, signalling strong analyst conviction and providing notable upside potential relative to the current share level. Article Title
• Neutral Sentiment: Incyte announced executive leadership appointments — a corporate governance update that may be viewed positively if it strengthens execution but is unlikely to move fundamentals immediately. Incyte Announces Executive Leadership Appointments
• Neutral Sentiment: Coverage piece assessing Incyte’s valuation after mixed short-term returns and strong one‑year performance — useful context for investors but not a direct near-term catalyst. A Look At Incyte (INCY) Valuation
• Neutral Sentiment: Multiple reports flagged a “significant” rise in short interest for March, but published figures show zero shares and NaN changes — likely a data/reporting anomaly. Investors should treat the short-interest headlines cautiously and monitor clearer data from exchanges.
• Negative Sentiment: UBS cut its price target from $104 to $94 and moved to a “neutral” rating, which narrows perceived upside and can weigh on sentiment among more conservative investors. Article Title
• Neutral Sentiment: A sector competitor (Karyopharm) reported mixed Phase 3 trial data in myelofibrosis — a development that may shift sector sentiment or competitive positioning but has uncertain direct impact on Incyte’s pipeline. Karyopharm myeloma drug yields mixed data in myelofibrosis trial

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.